SEC Comment Letter 0000000000-24-013517 to Neurogene Inc. (NGNE)
Neurogene Inc.
Date: Dec. 9, 2024 · CIK: 0001404644 · Accession: 0000000000-24-013517
AI Filing Summary & Sentiment
File numbers found in text: 333-283561
Letter
December 9, 2024 Rachel McMinn Chief Executive Officer Neurogene Inc. 535 W 24th St. 5th Floor New York, NY 10011 Re:Neurogene Inc. Registration Statement on Form S-1 Filed December 2, 2024 File No. 333-283561 Dear Rachel McMinn: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Branden C. Berns
Show Raw Text
December 9, 2024
Rachel McMinn
Chief Executive Officer
Neurogene Inc.
535 W 24th St.
5th Floor
New York, NY 10011
Re:Neurogene Inc.
Registration Statement on Form S-1
Filed December 2, 2024
File No. 333-283561
Dear Rachel McMinn:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Branden C. Berns